The new Tau NexGen E2814 clinical trial planned for DIAN-TU will be launching at most sites in 2022. This new trial design will offer individuals who have a dominantly inherited Alzheimer’s disease (DIAD) mutation access to investigational drugs that target both amyloid and tau. All participants will receive the anti-amyloid drug and also be randomized […]
Category: DIAN-TU Research Updates
Gantenerumab improved markers of disease in rare, inherited form of Alzheimer’s disease
Further analysis of data from an international trial of two investigational drugs in people in the early stages of a rare, inherited form of Alzheimer’s disease has demonstrated that one of the drugs had a positive impact on biomarkers of the disease. The study (ClinicalTrials.gov Identifier: NCT01760005) is a phase 2/3 trial led by Washington […]
Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates (Links to an external site)
Top-line data reported from international trial
A message from Dr. Bateman to DIAN-TU trial participants
Video
Update on the DIAN-TU-001 TRIAL: Janssen BACE Inhibitor (JNJ-54861911/atabecestat) DRUG ARM DISCONTINUATION
Update to the May 25th announcement found on Janssen’s website
DIAN-TU-001 Interim Analysis
Notice to DIAN-TU Investigational Sites and Participants
2015 Update
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) has completed the first stage of participant enrollment in the first Alzheimer’s prevention trial for autosomal dominant Alzheimer’s disease (ADAD), also referred to as early-onset Alzheimer’s disease. The goal of the first stage of the study is to determine the biomarker and cognitive effects of two different […]